FDA’s Woodcock calls to cut clinical costs via new efficiencies

By Zachary Brennan

- Last updated on GMT

FDA’s Woodcock calls to cut clinical costs via new efficiencies

Related tags Clinical trial

As the cost of clinical trials continues to grow, Janet Woodcock, director of the Center for Drug Evaluation and Research at the FDA told Senators earlier this week that there are “ways to greatly improve clinical trial efficiency,” and cut costs through the use of master protocols and real-world data.

Drug developers spend millions of dollars planning a trial, often times with CRO partners, developing an elaborate infrastructure to run it, finding and enlisting investigators, conducting the trials, and managing the data.

But, as Woodcock noted, “Each time a new drug is tested, the process is repeated, at great expense, only to dismantle the infrastructure when the study is completed. We believe that there are ways to greatly improve clinical trial efficiency, such as widespread use of clinical trial networks and master protocols, and we would like to work with you to examine those possibilities​.”

The FDA may look to take a page out of the book of the UK’s NIHR (National Institute for Health Research) clinical research network, which recently restructured​, and helps to support thousands of trials per year.


In addition to the master protocol idea for trials, Woodcock called to enhance the science of identifying and evaluating the utility of biomarkers, which can predict and evaluate the effects of proposed drugs before clinical testing and in people.

However, biomarkers based on new scientific understanding have been slow to come into clinical use, largely because the evidence supporting their validity has been lacking. The lack of new, well-understood biomarkers also impacts drug development, these new tests could speed evaluation of drug performance, including drug safety, and prediction of effectiveness. Similar to the problems with clinical trials, the scientific infrastructure for evaluating the validity of new biomarkers has not kept pace with the need for this activity​,” Woodcock added.

She also clarified that the FDA recognizes that there is still confusion about how new biomarkers can be qualified as some sponsors believe that many biomarkers are “stalled​” in the qualification process.

The actual case is that most of the programs in the biomarker qualification process are still in the evidence-gathering stage—which may take considerable time due to the need for more development work within the scientific community​,” Woodcock said.

Real-World Data

As the FDA approves therapies faster than any other developed country and more quickly than ever before, the agency will look to harness big data to track the safety of new drugs.

I have aggressively developed FDA’s Sentinel Initiative, a national electronic system that is transforming FDA’s ability to track the safety of drugs and biologics once they reach the market. Sentinel enables FDA to actively query diverse health care data sources—such as electronic health record systems, administrative and insurance claims databases, and registries—to evaluate possible medical product safety issues quickly and securely​,” Woodcock said.

But she also noted that “the science of using evidence from clinical experience to establish product effectiveness…is still in its infancy. So we must first develop the methodologies needed to harness its promise​.”

Related news

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more